Home/Pipeline/AmorphOX GLP-1

AmorphOX GLP-1

Metabolic Disorders

PreclinicalActive

Key Facts

Indication

Metabolic Disorders

Phase

Preclinical

Status

Active

Company

Orexo

About Orexo

Orexo is a publicly traded Swedish pharmaceutical company that has evolved from an R&D-focused entity into a commercial organization with a hybrid business model. Its strategic foundation is the proprietary AmorphOX® powder-based drug delivery technology, designed to improve bioavailability and stability for critical medicines. Following the transformative 2025 divestment of its flagship product Zubsolv® in the US, the company is executing a three-pillar growth strategy focused on becoming a global leader in nasal powder delivery, advancing a diversified pipeline to key value inflection points, and establishing technology partnerships.

View full company profile

Therapeutic Areas

Addiction Medicine Allergy/Immunology Metabolic Disorders Infectious Disease

Other Metabolic Disorders Drugs

Drug	Company	Phase	Status
Novel GLP-1 Receptor Agonist	Lupin	Pre-clinical/Clinical	Licensed (Gan & Lee)
Undisclosed Metabolic Program	Kallyope	Discovery	Active
Metabolic Disorders Program	Seragon Biosciences	Pre-clinical	Active
PPARγ Program	Micar Innovation	Discovery	Active
Pancreas-Targeting Capsids	rAAVen Therapeutics	Pre-clinical	Active
IVL-001	InVirtuoLabs	Discovery	Active
Amylin Program	Orion Biotechnology	Discovery	Active